GILD targets
BI's drug business would fit the bill - large, headquartered overseas, and many complementary areas of focus (but some overlap), except they probably don't want to be bought
I can see them having some interest in FGEN's IPF compound - different MOA from their Mab for IPF so could be complementary (and not constrained to subgroup). coincidentally FGEN's CEO cited control over scope and design of ph 3 for why they have rebuffed suitors thus far in the last cc, pretty much echoing what DD mentioned GILD likes - so not sure if they will see eye to eye
I also think if GILD wanted ICPT they likely wouldn't have bought a completing FXR agonist, but who knows
Market Data 
Markets 
AI
